OpenAI's 'Code Red' Moment: What Gemini's 750 Million Users Means for Europe's AI Market

OpenAI has paused multiple in-flight projects, including advertising integration, AI agents for health and shopping, and a personal assistant feature called Pulse. Teams have been temporarily reassigned, with daily coordination calls ensuring every available resource focuses on improving the core ChatGPT product. The company is also preparing to launch a new simulated reasoning model that Altman believes will outperform Gemini on key benchmarks.

"The leap is insane," said Marc Benioff, CEO of Salesforce, after publicly switching from ChatGPT to Gemini following three years of daily use. The remark landed hard in enterprise circles on both sides of the Atlantic.

What Is Driving Gemini's Growth

Gemini's ascent is not accidental. The model has consistently topped performance leaderboards, particularly on crowdsourced evaluation platforms where users compare outputs directly. Its one-million-token context window allows businesses to process vast volumes of information in a single session, making it particularly attractive for complex enterprise and clinical workflows.

A viral image-generation feature called Nano Banana brought millions of new users onto the platform, demonstrating once again that consumer adoption can be accelerated by a single, shareable creative tool. Sundar Pichai, CEO of Alphabet, confirmed the figures publicly: "Gemini had surpassed 750 million monthly active users, up from 650 million the previous quarter," he announced during Alphabet's Q4 2025 earnings call.

The European Dimension: Healthcare and Enterprise in the Crossfire

For European decision-makers, the platform battle between OpenAI and Google is not an abstract contest. Hospitals, insurers, and health-tech developers across the EU and UK are actively evaluating which large language model to anchor their clinical tools to. A shift in the underlying model's market position, pricing structure, or feature roadmap can unwind months of integration work.

The European AI ecosystem has its own perspective on this contest. Researchers at ETH Zurich, widely regarded as one of Europe's premier AI research institutions, have consistently argued that model diversity and open benchmarking are essential to preventing any single vendor from locking in the healthcare sector. Separately, Mistral AI, the Paris-based foundation model developer, has positioned itself as the European alternative precisely because enterprises worried about vendor concentration now have a credible sovereign option that complies natively with EU data-protection requirements.

The competitive pressure between OpenAI and Google may, paradoxically, benefit European AI providers. When the two American giants are locked in a features race, pricing tends to fall and APIs become more accessible, lowering the barrier for European health-tech startups to experiment with multiple models rather than committing to one.

Financial Pressure and What It Means for Buyers

OpenAI's predicament extends well beyond user metrics. Unlike Google, which can cross-subsidise AI development through its advertising and cloud businesses, OpenAI remains unprofitable while consuming substantial capital. Reuters columnist Robert Cyran highlighted OpenAI's "appetite for capital" as a structural vulnerability in a prolonged competition against a company with Alphabet's balance sheet.

This financial reality shapes decisions in ways that directly affect European customers. When OpenAI pauses its health-focused AI agents to focus on core ChatGPT performance, NHS trusts or German hospital networks that had been evaluating those tools face uncertainty. Enterprise procurement teams in the EU should factor financial runway and strategic stability into their vendor assessments, not just benchmark scores.

Google's integrated approach, embedding Gemini across Search, Workspace, Android, and cloud infrastructure, creates adoption pathways that a standalone chatbot product struggles to replicate. For European businesses already running on Google Workspace, the friction of adopting Gemini is considerably lower than switching to or maintaining a separate OpenAI subscription.

What European Regulators Are Watching

The concentration of AI user bases in two American platforms is not lost on EU policymakers. The AI Act, which entered into force in August 2024, includes provisions around general-purpose AI models and systemic risk that become directly relevant when a single platform commands 750 million monthly users. The European Commission's AI Office is responsible for overseeing the most capable general-purpose models, and market consolidation of this scale is precisely the scenario the systemic-risk provisions were designed to address.

European enterprises adopting either platform for regulated use cases, including clinical decision support, diagnostic imaging, or patient triage, need to ensure their deployment architecture satisfies both the AI Act and sector-specific rules under the EU Medical Device Regulation. Compliance is not a downstream concern to be retrofitted; it must be built into procurement and integration from the outset.

The Outlook: Competition Intensifies, Europe Must Stay Alert

OpenAI's emergency response reveals how quickly competitive dynamics shift in this industry. The company's planned reasoning model, its deepened university partnerships, and its enterprise refocus all suggest it is not conceding ground without a fight. ChatGPT still reports approximately 800 million weekly users, implying higher engagement frequency even if Gemini's monthly active user count has now closed the gap substantially.

For European organisations, the practical advice is straightforward: avoid single-vendor dependency, monitor the AI Act compliance obligations of whichever platform you deploy, and take seriously the European alternatives that are maturing rapidly. The battle between two American giants is consequential, but it does not have to dictate the terms on which European healthcare and enterprise AI develops.